AB0414 CROSS-CULTURAL ADAPTATION, CONVERGENT VALIDITY, AND RELIABILITY OF THE TURKISH VERSION OF THE COCHIN 17-ITEM SCLERODERMA FUNCTIONAL SCALE
Authors: N. G. Tore, D. Oskay, A. Avanoglu Guler, A. Tufan
Journal: Annals of the Rheumatic Diseases (2021)

Background: The Cochin 17-item Scleroderma Functional (CSF-17) Scale is a patient-reported outcome measure evaluating activities and participation in patients with systemic sclerosis (SSc). Objectives: The aim of the present study was to translate and cross-culturally adapt the CSF-17 into the Turkish language and investigate its convergent validity and reliability in Turkish-speaking patients with SSc. Methods: The CSF-17 was cross-culturally adapted according to Beaton’s guideline. Participants completed CSF-17 Scale, Scleroderma Health Assessment Questionnaire (SHAQ), Short Form-12 (SF-12) Health Survey and Hospital Anxiety and Depression Scale (HADS). Internal consistency and test-retest reliability were determined interpreting Cronbach’s alpha and Intraclass Correlation Coefficient (ICC) values, respectively. Convergent validity was tested using Pearson’s correlation coefficient. Results: Fifty-six patients with SSc were enrolled in the study. Cronbach’s alpha and ICC values of the CSF-17 total score were found to be as 0.963 and 0.958, respectively, indicating excellent reliability. As for the convergent validity, it was determined that CSF-17 total score has a good correlation with SHAQ. Correlations of subscales of CSF-17 with subscales of SF-12 and HADS ranged from poor to moderate (Table 1). Conclusion: Tukish version of CSF-17 met the set criteria of reliability and convergent validity. According to the results of the analysis, it was concluded that the Turkish version of the CSF-17 is a reliable and valid tool for Turkish-speaking SSc patients. References: [1]Daste C, Abdoul H, Foissac F et al. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17-item Scleroderma Functional scale. British Journal of Dermatology 2020; 183:710-718. [2]Beaton DE, Bombardier C, Guillemin F et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000; 25(24):3186-3191. [3]Karadag DT, Karakas F, Tekeoglu S et al. Validation of Turkish version of the Scleroderma Health Assessment Questionnaire. Clin Rheumatol, 2019,38(7):1917-1923. [4]Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care, 1996,34:220-233. [5]Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983,67:361-370. [6]Terwee CB, Bot SD, de Boer MR et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol, 2007,60:34–42. Table 1. Convergent validity of the CSF-17 Scales CSF-17 Section A Section B Total SHAQ 0.680** 0.640** 0.702** HADS-A 0.405* 0.472** HADS-D 0.460** 0.605** SF-12 MCS -0.482** -0.491** SF-12 PCS -0.745** -0.700** CSF-17: Cochin 17-item Scleroderma Functional scale, SHAQ: Scleroderma Health Assessment Questionnaire, HADS-A: Hospital Anxiety and Depression Scale-Anxiety, HADS-D: Hospital Anxiety and Depression Scale-Depression, SF 12 MCS: Short Form-12 Mental Component Score, SF-12 PSC: Short Form-12 Physical Component Score. *p&lt;0.05, **p&lt;0.001 Disclosure of Interests: None declared